Wells Fargo & Co began coverage on shares of Avrobio (NASDAQ:AVRO) in a report published on Monday morning, Marketbeat Ratings reports. The brokerage issued an outperform rating and a $40.00 price target on the stock.

Several other research analysts also recently commented on the company. Cowen began coverage on Avrobio in a research report on Monday. They issued an outperform rating on the stock. Morgan Stanley began coverage on Avrobio in a research report on Monday. They issued an overweight rating and a $37.00 price target on the stock. Finally, Wedbush began coverage on Avrobio in a research report on Monday. They issued an outperform rating and a $38.00 price target on the stock.

Shares of NASDAQ AVRO opened at $34.50 on Monday. Avrobio has a 12 month low of $26.51 and a 12 month high of $35.96.

Avrobio Company Profile

AVROBIO, Inc, a clinical stage gene therapy company, focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. It lead product candidate in AVR-RD-01, which is in Phase 1 clinical trial for the treatment of Fabry disease. The company is also developing AVR-RD-02 for the treatment of Gaucher disease; AVR-RD-03 for the treatment of Pompe disease; and AVR-RD-04 for the treatment of cystinosis.

Featured Story: What is a closed-end mutual fund (CEF)?

Receive News & Ratings for Avrobio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avrobio and related companies with MarketBeat.com's FREE daily email newsletter.